Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Vanzacaftor

Home DrugsVanzacaftor

Investigational

Small Molecule

Vanzacaftor

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Technical identifiers

Chemical Formula: C₃₂H₃₉N₇O₄S
CAS Number: 2374124-49-7
UNII ID: COM1POP492

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS
EP 4218754 B1Applicant: VERTEX PHARMAPriority: 2018
EP
COMBINATION OF VANZACAFTOR, TEZACAFTOR, DEUTIVACAFTOR FOR USE IN TREATING CYSTIC FIBROSIS
WO 2025166342 A1Applicant: VERTEX PHARMAPriority: 2024
WO
VANZACAFTOR ENANTIOMER FOR BK POTENTIATION IN AIRWAY DISEASES
WO 2026143092 A1Applicant: UNIV KANSASPriority: 2024
WO